# Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

> **NCT01138111** · PHASE1 · COMPLETED · sponsor: **Life Molecular Imaging SA** · enrollment: 45 (actual)

## Conditions studied

- Alzheimer Disease
- Amyloid Beta-Protein

## Interventions

- **DRUG:** Florbetaben (BAY94-9172)

## Key facts

- **NCT ID:** NCT01138111
- **Lead sponsor:** Life Molecular Imaging SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138111, "Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01138111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*